



# MATERIAL SAFETY DATA SHEET

Revision date: 18-Sep-2008

Version: 1.3

Page 1 of 6

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**Pfizer Inc**  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222

**Pfizer Ltd**  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

**Emergency telephone number:**  
CHEMTREC (24 hours): 1-800-424-9300  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**  
ChemSafe (24 hours): +44 (0)208 762 8322

### Material Name: Cabergoline Tablets

<b>Trade Name:</b>	DOSTINEX; CABASER
<b>Chemical Family:</b>	Mixture
<b>Intended Use:</b>	Pharmaceutical product used for lactation inhibition

## 2. HAZARDS IDENTIFICATION

<b>Appearance:</b>	White tablets
<b>Statement of Hazard:</b>	Non-hazardous in accordance with international standards for workplace safety.
<b>Additional Hazard Information:</b>	
<b>Short Term:</b>	Active ingredient may be harmful if swallowed. (based on animal data) . Accidental ingestion may cause effects similar to those seen in clinical use.
<b>Known Clinical Effects:</b>	Ingestion of this material may cause effects similar to those seen in clinical use including nausea, vomiting, abdominal cramps, anorexia, diarrhea, and constipation. This drug may decrease the quantity/quality of breast milk.
<b>EU Indication of danger:</b>	Not classified

<b>Australian Hazard Classification (NOHSC):</b>	Non-Hazardous Substance. Non-Dangerous Goods.
--	---

<b>Note:</b>	This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
--------------	--

## MATERIAL SAFETY DATA SHEET

Material Name: Cabergoline Tablets  
Revision date: 18-Sep-2008

Page 2 of 6  
Version: 1.3

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Cabergoline	81409-90-7	Not listed	Xn;R22	1.25

Ingredient	CAS Number	EU EINECS/ELINCS List	Classification	%
Leucine	61-90-5	200-522-0	Not Listed	*
Lactose NF, anhydrous	63-42-3	200-559-2	Not Listed	*

**Additional Information:** \* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:** Not applicable

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

# MATERIAL SAFETY DATA SHEET

Material Name: Cabergoline Tablets  
Revision date: 18-Sep-2008

Page 3 of 6  
Version: 1.3

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

**General Handling:** Restrict access to work area. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**Storage Conditions:** Store as directed by product packaging.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Leucine**  
Latvia OEL - TWA Listed

**Cabergoline**  
Pfizer Occupational Exposure Band (OEB): OEB5 (control exposure to <1ug/m<sup>3</sup>)

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.  
**Environmental Exposure Controls:** Refer to specific Member State legislation for requirements under Community environmental legislation.  
**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Not required for the normal use of this product. Wear protective gloves when working with large quantities.  
**Eyes:** Not required for the normal use of this product. Wear safety glasses or goggles if eye contact is possible.  
**Skin:** Not required for the normal use of this product. Wear protective clothing when working with large quantities.  
**Respiratory protection:** Not required for the normal use of this product. Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, with appropriate protection factors, should be used to minimize exposure.

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

<b>Physical State:</b>	Tablets	<b>Color:</b>	White
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

## 10. STABILITY AND REACTIVITY

**Stability:** Stable at normal conditions  
**Conditions to Avoid:** None known  
**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers  
**Hazardous Decomposition Products:** Nitrogen oxides (nox) Carbon oxides

## MATERIAL SAFETY DATA SHEET

Material Name: Cabergoline Tablets  
Revision date: 18-Sep-2008

Page 4 of 6  
Version: 1.3

### 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the active ingredient(s).

#### **Acute Toxicity: (Species, Route, End Point, Dose)**

##### **Cabergoline**

Rat Oral LD 50 383 (F) mg/kg  
Rat Intravenous LD 50 22mg/kg  
Mouse Oral LD 50 202 (F)mg/kg  
Mouse Intravenous LD 50 24 (F)mg/kg

#### **Irritation / Sensitization: (Study Type, Species, Severity)**

##### **Cabergoline**

Skin Sensitization - GPMT Guinea Pig No effect

#### **Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))**

##### **Cabergoline**

Embryo / Fetal Development Rat Oral 0.012 mg/kg/day LOAEL Fetotoxicity  
Embryo / Fetal Development Rabbit Oral 8 mg/kg/day NOAEL Not Teratogenic  
Embryo / Fetal Development Mouse Oral 8 mg/kg/day Not Teratogenic, Maternal Toxicity

#### **Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

##### **Cabergoline**

*In Vitro* Mammalian Cell Mutagenicity Hamster Negative  
*In Vitro* Chromosome Aberration Human Lymphocytes Negative  
*In Vitro* Micronucleus Mouse Bone Marrow Negative  
*In Vitro* Direct DNA Damage Bacteria Negative  
Bacterial Mutagenicity (Ames) *Salmonella* Negative

#### **Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

##### **Cabergoline**

24 Month(s) Rat Oral 0.320 mg/kg/day Not carcinogenic  
21 Month(s) Mouse Oral 0.980 mg/kg/day Not carcinogenic

#### **Carcinogen Status:**

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

### 12. ECOLOGICAL INFORMATION

#### **Environmental Overview:**

Environmental properties have not been investigated. Releases to the environment should be avoided.

# MATERIAL SAFETY DATA SHEET

Material Name: Cabergoline Tablets  
Revision date: 18-Sep-2008

Page 5 of 6  
Version: 1.3

## 12. ECOLOGICAL INFORMATION

## 13. DISPOSAL CONSIDERATIONS

### Disposal Procedures:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

EU Indication of danger: Not classified

### OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

### Canada - WHMIS: Classifications

#### WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

### Cabergoline

Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
---	------------

### Leucine

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-522-0

### Lactose NF, anhydrous

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	200-559-2

## MATERIAL SAFETY DATA SHEET

Material Name: Cabergoline Tablets  
Revision date: 18-Sep-2008

Page 6 of 6  
Version: 1.3

### 15. REGULATORY INFORMATION

### 16. OTHER INFORMATION

#### Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

**Data Sources:**

Pfizer proprietary drug development information. Publicly available toxicity information.

**Reasons for Revision:**

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 13 - Disposal Considerations.

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**